| APC | antigen-presenting cell(s) |
| ATL | adult T-cell leukemia/lymphoma |
| AZA | azacitidine |
| BV | brentuximab vedotin |
| EZH1/2 | enhancer of zeste homolog 1/2 |
| GVHD | graft-versus-host disease |
| GVL | graft-versus-lymphoma |
| HCT | allogenic hematopoietic cell transplantation |
| HDACis | histone deacetylase inhibitors |
| irAEs | immune-related adverse events |
| LEN | lenalidomide |
| MOG | mogamulizumab |
| NK | natural killer |
| NRM | non-relapse mortality |
| PD-1 | programmed cell death protein 1 |
| PTCy | post-transplant cyclophosphamide |
| TCLs | T-cell Lymphomas |
| Treg | regulatory T cell(s) |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.